Stock & Company Details
Haemonetics Corp. $HAE
Price:
N/A
N/A
45M
$5.4B
52 Week High:
N/A
10 Day Average Volume:
N/A
58.27
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
HAE technical indicators
Latest Haemonetics Corp. (HAE) indicator readings as of 2026-10-09.
HAE's 14-day RSI is 74.5, in overbought territory. At $118.69 it is trading 56.7% above its 200-day moving average of $75.75, and above its 50-day average of $101.61. Price sits above the upper Bollinger Band ($98.63 to $115.79). ADX reads 28.1, indicating a trending market.
HAE backtested strategy results
How 4 rule-based strategies performed on Haemonetics Corp. (HAE) over recent history, last backtested 2026-10-10. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +96.6% | 50% | 16 | -31.5% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -33.2% | 26% | 27 | -59.0% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -27.2% | 39% | 31 | -48.7% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +30.1% | 62% | 29 | -40.1% |
Overview
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Finance Bot
Ask your questions
Start by typing a question below.
